| RCEEX | VGWLX | RCEEX / VGWLX | |
| Total Expense Ratio | 1.06 | 0.43 | 247% |
| Annual Report Gross Expense Ratio | 1.06 | 0.43 | 247% |
| Fund Existence | 12 years | 9 years | - |
| Gain YTD | 8.189 | 11.401 | 72% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 3000 | 8% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 131B | 3.31B | 3,954% |
| Annual Yield % from dividends | 2.24 | 2.65 | 85% |
| Returns for 1 year | 6.23 | 12.48 | 50% |
| Returns for 3 years | 40.14 | 29.95 | 134% |
| Returns for 5 years | 35.96 | 22.49 | 160% |
| Returns for 10 years | 64.93 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VITNX | 125.10 | N/A | N/A |
| Vanguard MStar Inst Ttl Stk Mkt IdxInstl | |||
| JFCAX | 36.52 | N/A | N/A |
| JHancock Fundamental All Cap Core A | |||
| FBTDX | 171.24 | N/A | N/A |
| Franklin Biotechnology Discovery C | |||
| GSUKX | 25.56 | N/A | N/A |
| Goldman Sachs International Eq Inc R6 | |||
| HLFZX | 9.72 | N/A | N/A |
| Harding Loevner Frontier Emerg MktsInstZ | |||